Applied Pharmaceutical Toxicology

Event details

Website:
Location: Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, United States, Europe
About

Speakers Confirmed for 2018

  • Barry Astroff, Director, Novartis Institutes for BioMedical Research (NIBR)
  • Vladimir Bantseev, Scientist/Toxicologist, Genentech
  • Giulio Barteselli, Associate Medical Director, Clinical Ophthalmology, Genentech
  • Sarah Campion, Senior Principal Scientist, Developmental and Reproductive Toxicology, Pfizer
  • Steven Cassar, Senior Scientist II, AbbVie
  • Paul Cornwell, Senior Research Scientist, Eli Lilly
  • Deidre Dalmas, Principal Scientist/Toxicologist, GSK
  • Kevin French, Project Toxicologist, GSK
  • Claudette Fuller, Senior Principal Scientist, Merck
  • Maia Green, Principal Scientist, Merck
  • Larissa Lapteva, Acting Director, Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration
  • Dong Lee, Discovery Toxicology, Genentech
  • Steven Laing, Pathologist-Scientist, Genentech
  • Jonathan Maher, Senior Scientist, Discovery Toxicology, Genentech
  • Curtis Maier, Director, Immunology, GSK
  • Jenny Marlowe, Senior Director, Preclinical Development, bluebird bio
  • Mark Milton, Ophthalmology Therapeutic Area Head, PK Sciences, Novartis Institutes for BioMedical Research (NIBR)
  • Padma Narayanan, Executive Director, Toxicology, Ionis Pharmaceuticals
  • John Nicolette, Senior Principal Research Scientist, AbbVie
  • Judith Prescott, Executive Director, Program Development, Safety Assessment, Merck
  • Haleh Saber, Deputy Director, (OHOP/DHOT), FDA

 

Proposed Sessions for the Discovery Toxicology Workshop

  • Session I:  When Knowledge is Power: Impactful Investigative Toxicology Case Studies
  • Session II:  Falling Off the Needle: Acute Anaphylactoid Reactions
  • Session III:  Hot Topics in Discovery Toxicology

 

Proposed Sessions for the Development Toxicology Workshop

  • Session IV:  Impurities and Occupational Exposure Limits / Health Hazard Categorization
  • Session V:   Regulatory Guidance Development and Updates
  • Session VI:  Key Learning from Recent Clinical Trial Experiences